Avoid common mistakes on your manuscript.
Erratum to: Adv Ther DOI 10.1007/s12325-017-0524-9
The authors of the above mentioned paper would like to make the following amendment to the author affiliations.
Kazumi Tagawa’s affiliation currently reads “Department of Surgery, Shioda Hospital, Katsuura City, Japan”. The affiliation should read “Department of Gastroenterology, Mitsui Memorial Hospital, Tokyo, Japan”.
Finally, the authors would like to make the following amendments to Fig. 2. The x-axis labels for both Fig. 2a and Fig. 2b currently read "Time from TACE refractory (years)". The labels should read "Time (years)". The corrected Fig. 2 is provided here.
Cumulative survival rates for a SOR vs. CON and b mSOR vs. mCON. CON transcatheter arterial chemoembolization, mCON matched transcatheter arterial chemoembolization, mSOR matched sorafenib, SOR sorafenib
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s12325-017-0524-9.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Ohki, T., Kondo, M., Karasawa, Y. et al. Erratum to: Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index. Adv Ther 34, 1773–1774 (2017). https://doi.org/10.1007/s12325-017-0539-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-017-0539-2